Revvity raised its full-year outlook to pro forma adjusted EPS of $5.40 to $5.45 after beating expectations on both lines. An Investor Day on November 13 adds detail on the turnaround.
Revvity Inc
24/7 Wall St. View
RVTY at a Glance
- Market cap
- $16.9B
- P/E ratio
- 67.4
- Dividend yield
- 0.18%
- Revenue (TTM)
- $2.9B
- Profit margin
- 8.6%
- EPS (TTM)
- $2.25
- 52-week range
- $81 – $172
- 24/7 target
- $180.22
- Street target
- $171.40
- Next report
- Feb 1, 2027
Headquartered in Waltham, MA Fiscal year ends December NYSE: RVTY revvity.com
About Revvity
Revvity, Inc. (NYSE: RVTY) provides health science solutions, technologies, expertise and services that deliver workflows from discovery to development and from diagnosis to cure. It reports two segments. Life Sciences supplies research tools and technologies to pharmaceutical, biotech and academic customers. Diagnostics serves diagnostic labs and governments with screening, detection and diagnosis solutions. Its specialized focus areas include translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, and informatics. Revvity had 2025 revenue of $2.9 billion, approximately 11,000 employees and customers in more than 160 countries, and is part of the S&P 500. In July 2026 the company agreed to divest its Immunodiagnostics business in China (China IDX), about 6% of fiscal 2025 revenue, with closing expected by the end of 2027. The company is also pursuing a transformation program to modernize business processes, automate and implement global systems under the Revvity Business Model. Updated
Frequently Asked Questions
What does Revvity do?
Revvity, Inc. (NYSE: RVTY) provides health science solutions, technologies, expertise and services that deliver workflows from discovery to development and from diagnosis to cure. It reports two segments.
What is the RVTY stock price target?
24/7 Wall St.'s 12-month price target for RVTY is $180.22, rated Buy. The Wall Street consensus target is $171.40. RVTY price prediction →